Fold change from baseline in anti-
B hepatitis B
Per-protocol immunogenicity population. Vaccinations were administered on study days 1, 57, and 113. Error bars represent 95% confidence intervals. Euvax B hepatitis B recipients were pooled across cohorts.When assessed by ANCOVA, there were no significant differences in adjusted mean log IgG antibody responses at study day 127 between those who were vaccinated with 